Sinovac Biotech Ltd (SVA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Sinovac Biotech Ltd stock (SVA) is currently trading at $6.47. Sinovac Biotech Ltd PE ratio is 6.66. Sinovac Biotech Ltd PS ratio (Price-to-Sales) is 1.83. Analyst consensus price target for SVA is $3.52. WallStSmart rates SVA as Buy.
- SVA PE ratio analysis and historical PE chart
- SVA PS ratio (Price-to-Sales) history and trend
- SVA intrinsic value — DCF, Graham Number, EPV models
- SVA stock price prediction 2025 2026 2027 2028 2029 2030
- SVA fair value vs current price
- SVA insider transactions and insider buying
- Is SVA undervalued or overvalued?
- Sinovac Biotech Ltd financial analysis — revenue, earnings, cash flow
- SVA Piotroski F-Score and Altman Z-Score
- SVA analyst price target and Smart Rating
Sinovac Biotech
📊 No data available
Try selecting a different time range
SVA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Sinovac Biotech Ltd (SVA)
SVA trades at a significant discount to its Graham intrinsic value of $45.44, offering a 86% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Sinovac Biotech Ltd (SVA) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, price/sales. Overall metrics suggest strong investment potential with favorable risk/reward.
Sinovac Biotech Ltd (SVA) Key Strengths (7)
Every $100 of shareholder equity generates $25 in profit
Keeps $42 of every $100 in revenue after operating costs
Revenue surging 303.70% year-over-year
Earnings per share surging 354.80% year-over-year
Keeps $22 of every $100 in revenue as net profit
Paying $1.83 for every $1 of annual revenue
Trading at 1.82x book value, attractively priced
Supporting Valuation Data
Sinovac Biotech Ltd (SVA) Areas to Watch (2)
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 32.02%
Supporting Valuation Data
Sinovac Biotech Ltd (SVA) Detailed Analysis Report
Overall Assessment
This company scores 78/100 in our Smart Analysis, earning a B+ grade. Out of 9 metrics analyzed, 7 register as strengths (avg 9.4/10) while 2 fall into concern territory (avg 5.5/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, Revenue Growth. Valuation metrics including Price/Sales (1.83), Price/Book (1.82) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 25.20%, Operating Margin at 42.30%, Profit Margin at 21.60%. Growth metrics are encouraging with Revenue Growth at 303.70%, EPS Growth at 354.80%.
The Bear Case
The primary concerns are Market Cap, Institutional Own..
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Market Cap improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 25.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 303.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of Return on Equity and Operating Margin makes a compelling case at current levels. The key risk is Market Cap, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B+ grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SVA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SVA's Price-to-Sales ratio of 1.83x sits near its historical average of 1.83x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 1.83x set in Mar 2026, and 0% above its historical low of 1.83x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Sinovac Biotech Ltd (SVA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Sinovac Biotech Ltd is a strong growth company balancing expansion with improving profitability. Revenue reached 511M with 304% growth year-over-year. Profit margins are strong at 21.6%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 304% YoY, reaching 511M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 2520.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Sinovac Biotech Ltd maintain 304%+ revenue growth, or will competition slow it down?
Dividend sustainability with a current yield of 8.5%. Watch payout ratio and free cash flow coverage.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Sinovac Biotech Ltd.
Bottom Line
Sinovac Biotech Ltd offers an attractive blend of growth (304% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:26:26 AM
About Sinovac Biotech Ltd(SVA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
China
Sinovac Biotech Ltd., a biopharmaceutical company, focuses on the research, development, manufacture and marketing of vaccines against human infectious diseases in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.